Among the numerous biomarkers, only IDH mutations, MGMT promoter methylation, and 1p19q codeletion are being routinely used in clinic diagnosis for glioma patients,21 while other biomarkers are still in observation phage in clinical trials. This evidence concerns the gene IDH1 and glioma.